{"nctId":"NCT00128713","briefTitle":"Optimal Platelet Dose Strategy for Management of Thrombocytopenia","startDateStruct":{"date":"2004-07"},"conditions":["Thrombocytopenia"],"count":1351,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Lower Dose Prophylactic Platelet Transfusions"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Medium Dose Prophylactic Platelet Transfusions"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Higher Dose Prophylactic Platelet Transfusions"]}],"interventions":[{"name":"Medium Dose Prophylactic Platelet Transfusions","otherNames":[]},{"name":"Lower Dose Prophylactic Platelet Transfusions","otherNames":[]},{"name":"Higher Dose Prophylactic Platelet Transfusions","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has, or is expected to have, hypoproliferative thrombocytopenia, and is expected to have a platelet count of up to 10,000 ul for at least 5 days and be in the hospital for at least 5 days\n* Weight is between 10 and 135 kilograms\n* PT/INR, PTT, and fibrinogen assays that are measured within 72 hours before study entry are as follows:\n\n  1. PT less than or equal to 1.3 times the upper limit of normal for the laboratory\n  2. PTT less than or equal to 1.3 times the upper limit of normal for the laboratory\n  3. Fibrinogen greater than or equal to 100 mg/dl\n* Undergoing, or has completed, hematopoietic stem cell transplantation, for any diagnosis; OR has a diagnosis of acute or chronic leukemia, non-Hodgkins or Hodgkins lymphoma, myeloma, myelodysplasia, or non-hematologic malignancy and is undergoing, or has completed, chemotherapy\n* During this hospitalization, the patient has not yet received any platelet transfusions related to the current or planned course of therapy (individual platelet transfusions given prior to the study and unrelated to thrombocytopenia will not exclude the patient)\n\nExclusion Criteria:\n\n* Evidence of greater than or equal to Grade 2 bleeding (as determined by the Platelet Dose Trial Bleeding Scale)\n* Receiving antithrombotic drugs\n* Will receive bedside leuko-reduced platelet transfusions\n* Present, or history of, platelet transfusion refractoriness within 30 days prior to study entry\n* Pre-enrollment lymphocytotoxic antibody screen (PRA) known to be greater than or equal to 20% based on prior data\n* Present, or history of, acute promyelocytic leukemia (APML), immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic-uremic syndrome (HUS)\n* Will be transfused at platelet trigger of greater than 10,000 platelets/ul\n* Recent history of major surgery (within 2 weeks of study entry)\n* Currently taking, or participating in a study involving, platelet substitutes, platelet growth factors, or pharmacologic agents intended to enhance or decrease platelet hemostatic function\n* Pregnant\n* Previously enrolled in this study","healthyVolunteers":false,"sex":"ALL","maximumAge":"100 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"At Least One Day With Grade 2 or Higher Bleeding","description":"Any Grade 2 (moderate) or higher grade bleeding, as determined by daily hemostatic assessment and documentation of any red blood cell transfusions to treat bleeding","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"304","spread":null},{"groupId":"OG001","value":"293","spread":null},{"groupId":"OG002","value":"299","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Platelet Utilization","description":"Total number of platelets transfused, based on attempted dose, among subjects who have at least one platelet transfusion and no missing data on attempted doses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.96","spread":null},{"groupId":"OG001","value":"12.49","spread":null},{"groupId":"OG002","value":"22.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Platelet Transfusion Episodes","description":"Number of platelet transfusion episodes among subjects who have at least one platelet transfusion and no missing data on attempted doses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Bleeding Severity, if a Suitable Scale is Validated and Published by the Time the Trial Ends","description":"No suitable scale was identified, so no analyses for this outcome were carried out","classes":[]},{"type":"SECONDARY","title":"Highest Grade of Bleeding While on Study","description":"Highest grade of bleeding during time on study using Platelet Dose Trial modification of World Health Organization Bleeding Scale. Grades 0-1 (no or minimal bleeding), 2 (moderate bleeding), 3 (bleeding generally requiring red cell transfusion), 4 (severe bleeding)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":null},{"groupId":"OG001","value":"244","spread":null},{"groupId":"OG002","value":"249","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":38,"n":453},"commonTop":["Fever","Allergic Reaction/Hypersensitivity","Rigors, chills","Sinus Tachycardia","Hypertension"]}}}